Clinical Trial Update: A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating VX-661/Ivacaftor in cystic fibrosis patients homozygous for F508del-CFTR; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-661/Ivacaftor (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2018-07-27